SIREN : 434018990
BSN MEDICAL SAS is a French company founded 25 years ago, specialized in the sector Fabrication de préparations pharmaceutiques. Based in VIBRAYE (72320), this company of category GE shows in 2024 a revenue of 39.3 M€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Data updated on 2026-05-09
Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy
| Indicator | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 39 293 296 € | 43 568 101 € | 37 078 026 € | 29 531 469 € | 26 540 915 € | 34 055 077 € | 35 829 807 € | 37 278 245 € | 40 093 967 € |
| Net income | 3 217 010 € | 5 014 999 € | 2 552 032 € | 2 065 427 € | 153 204 € | 1 212 881 € | 2 580 602 € | 2 829 461 € | 591 542 € |
| EBITDA | 3 740 434 € | 7 237 690 € | 2 691 660 € | 2 598 845 € | 1 259 436 € | 6 680 961 € | 8 082 048 € | 8 412 384 € | 10 447 625 € |
| Net margin | 8.2% | 11.5% | 6.9% | 7.0% | 0.6% | 3.6% | 7.2% | 7.6% | 1.5% |
In 2024, BSN MEDICAL SAS achieves revenue of 39.3 M€. Activity remains stable over the period (CAGR: -0.3%). Slight decline of -10% vs 2023. After deducting consumption (20.3 M€), gross margin stands at 18.9 M€, i.e. a rate of 48%. This ratio measures the ability to generate value from commercial activity. EBITDA (= Gross margin - Personnel expenses - Taxes) reaches 3.7 M€, representing 9.5% of revenue. Warning negative scissor effect: despite revenue change (-10%), EBITDA varies by -48%, reducing margin by 7.1 pts. This reflects costs rising faster than revenue. This level of operating margin is satisfactory for the sector. Ultimately, net income (= EBIT +/- financial result +/- exceptional - corporate tax) amounts to 3.2 M€, i.e. 8.2% of revenue. This profit can be retained or distributed to shareholders.
39 293 296 €
18 947 885 €
3 740 434 €
3 358 505 €
3 217 010 €
9.5%
The debt ratio (= Financial debt / Equity x 100) stands at 0%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches 88%. This high autonomy means the company finances most of its assets through equity, a sign of strength. Cash flow represents 9.1% of revenue. Cash flow measures resources generated by operations, available for investment and debt repayment. Satisfactory level allowing partial financing of growth.
0.0%
87.734%
9.07%
0.0
13.2%
In 2024, the debt ratio of BSN MEDICAL SAS (0.00) ranks in the bottom 25% of the sector, which is positive. This ratio measures the weight of debt relative to equity. A low ratio indicates a solid financial structure with little dependence on creditors.
In 2024, the financial autonomy of BSN MEDICAL SAS (87.7%) ranks in the top 25% of the sector. This ratio represents the share of equity in total financing. High autonomy reflects financial independence and ability to absorb shocks.
In 2024, the repayment capacity of BSN MEDICAL SAS (0.00) ranks in the bottom 25% of the sector, which is positive. This ratio indicates the number of years needed to repay debt with cash flow. A short capacity reflects controlled debt and good cash generation.
The liquidity ratio (= Current assets / Current liabilities) stands at 573.00. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.
573.001
-7.813
In 2024, the liquidity ratio of BSN MEDICAL SAS (573.00) ranks in the top 25% of the sector. This ratio measures the ability to cover short-term debt with current assets. A ratio above 1 ensures comfortable coverage of short-term maturities.
In 2024, the interest coverage of BSN MEDICAL SAS (-7.8x) ranks in the bottom 25% of the sector. This ratio indicates how many times operating income covers interest expenses. Low coverage may indicate fragility to rate or income variations.
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 25 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 44 days. Favorable situation: supplier credit is longer than customer credit by 19 days. Inventory turnover is 38 days (= Average inventory / Cost of goods x 360). Fast turnover, sign of good inventory management. Overall, WCR represents 284 days of revenue, i.e. 31.0 M€ to permanently finance.
31 017 342 €
25 j
44 j
38 j
284 j
Indicative estimate only : the number of comparable transactions in this sector is limited (27 transactions). This range of 641 855€ to 1 972 812€ is provided for information purposes only and requires in-depth analysis to be confirmed.
This estimate is based on the analysis of 27 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Compare BSN MEDICAL SAS with other companies in the same sector:
Voir toutes les statistiques du secteur Fabrication de préparations pharmaceutiques
The revenue of BSN MEDICAL SAS in 2024 is 39.3 M€.
Yes, BSN MEDICAL SAS generated a net profit of 3.2 M€ in 2024.
The headquarters of BSN MEDICAL SAS is located in VIBRAYE (72320), in the department Sarthe.
The tax return of BSN MEDICAL SAS is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
BSN MEDICAL SAS operates in the sector Fabrication de préparations pharmaceutiques (NAF code 21.20Z). See the 'Sector positioning' section above to compare the company with its competitors.